by jtcir-auto | May 10, 2021 | Press Releases
– Live video webcast with CEO, Dr. Klaus Paulini, onMonday, May 17, 2021 at 8:45 AM ETCHARLESTON, S.C., May 10, 2021 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company...
by jtcir-auto | May 6, 2021 | Press Releases
-In collaboration, Aeterna and The University of Sheffield, UK have selected the development candidate AEZS-150, a parathyroid hormone (PTH) fusion polypeptide to start the formal preclinical development for potentially enabling the first in human clinical...
by jtcir-auto | May 6, 2021 | Press Releases
-In collaboration, Aeterna and The University of Sheffield, UK have selected the development candidate AEZS-150, a parathyroid hormone (PTH) fusion polypeptide to start the formal preclinical development for potentially enabling the first in human clinical...
by jtcir-auto | May 5, 2021 | Press Releases
CHARLESTON, S.C., May 05, 2021 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of...
by jtcir-auto | May 5, 2021 | Press Releases
CHARLESTON, S.C., May 05, 2021 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of...